{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:26:38Z","timestamp":1748823998645},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T00:00:00Z","timestamp":1181952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>While empiric acid\u2010suppressive therapy for uninvestigated dyspepsia patients with symptoms of epigastric pain or burning is standard practice, it is unknown whether an early response to therapy predicts outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate whether a 1\u2010w acid suppression trial is effective for predicting 8\u2010w response in such patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> <jats:italic>Helicobacter pylori<\/jats:italic>\u2010negative patients (aged 18\u201350\u2003years) in primary care with uninvestigated epigastric pain or burning were randomized to esomeprazole 40\u2003mg q.d.s. or b.d. for 1w, followed by esomeprazole 40\u2003mg q.d.s. or placebo for 7w. Each day, patients rated the severity of their symptoms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Based on the last 3d, 1\u2010w response rates were 39% (231 of 588) and 43% (258 of 596) with esomeprazole 40\u2003mg q.d.s. and b.d., respectively. Based on the last 7d, response rates at 4w were 38% (283 of 738) and 25% (93 of 380) for esomeprazole and placebo, respectively, and 47% (339 of 716) and 34% (124 of 368), respectively, at 8w (both <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001 vs. placebo). The sensitivity and specificity of esomeprazole treatment were 58% and 70%, respectively, at 8w.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A 1\u2010w acid suppression trial is of limited clinical value for predicting 8\u2010w response in patients with symptoms of epigastric pain or burning. Esomeprazole provides greater symptom control than placebo at 4w and 8w.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03409.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T12:03:55Z","timestamp":1279886635000},"page":"665-672","source":"Crossref","is-referenced-by-count":22,"title":["One\u2010week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8\u2003weeks\u2019 treatment with esomeprazole: a randomized, placebo\u2010controlled study"],"prefix":"10.1111","volume":"26","author":[{"given":"S. V.","family":"VAN ZANTEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"FLOOK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. J.","family":"TALLEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"VAKIL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"LAURITSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"BOLLING\u2010STERNEVALD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"PERSSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"BJ\u00d6RCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2010E.","family":"SVEDBERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ON BEHALF OF THE STARS II STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii37"},{"key":"e_1_2_6_3_2","first-page":"S3","article-title":"An evidence\u2010based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori","volume":"12","author":"Veldhuyzen van Zanten S","year":"2000","journal-title":"CMAJ"},{"key":"e_1_2_6_4_2","unstructured":"The British Society of Gastroenterology guidelines on dyspepsia. Available at:http:\/\/www.bsg.org.uk\/pdf_word_docs\/dyspepsia.doc 2007."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.09.020"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00225.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00410.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001960"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.01.008"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90531-2"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6943.1552"},{"key":"e_1_2_6_12_2","first-page":"866","article-title":"Number needed to treat","volume":"52","author":"Rao G","year":"2003","journal-title":"J Fam Pract"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii69"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30089.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40280.x"},{"key":"e_1_2_6_16_2","first-page":"660","article-title":"Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials","volume":"91","author":"Veldhuyzen van Zanten SJ","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.059"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.0284f.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.07123.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03409.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03409.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:02:29Z","timestamp":1697234549000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03409.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,16]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03409.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03409.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2007,6,16]]}}}